Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Eledon Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 33 | 28 | −5 |
| Shares | 9.28M | 8.92M | −357.8K (−3.9%) |
| Value | $12.7M | $12.2M | −$490.8K (−3.9%) |
New holders (3)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pathstone Family Office, LLC | 13,029 | $17.9K | 0.00% |
| RMB Capital Management, LLC | 10,000 | $13.7K | 0.00% |
| JPMorgan Chase & Co | 26 | $36 | 0.00% |
Sold out (8)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Ikarian Capital, LLC | 221,830 | $303.9K |
| Boothbay Fund Management, LLC | 22,050 | $30.2K |
| Virtu Financial LLC | 17,675 | $24.0K |
| Jane Street Group, LLC | 15,783 | $21.6K |
| Veritable, L.P. | 13,029 | $17.9K |
| Two Sigma Investments, LP | 10,586 | $14.5K |
| Citadel Advisors LLC | 7,740 | $10.6K |
| UBS Group AG | 32 | $44 |